Danimer Scientific (DNMR) 10-Q 18 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Document Information [Line Items]
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	(229)
Local Phone Number	243-7075
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		85,536,515
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Warrant to Purchase [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	DNMR WS
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 312,910	$ 377,581
Accounts receivable, net	10,114	6,605
Inventory	16,846	13,642
Prepaid expenses and other current assets	4,565	3,089
Contract assets	1,397	1,466
Total current assets	345,832	402,383
Property, plant and equipment, net	129,577	106,795
Patents, net	1,764	1,801
Right-of-use assets	19,329	19,387
Leverage loans receivable	13,408	13,408
Restricted cash	2,320	2,316
Other noncurrent assets	73	111
Total assets	512,303	546,201
Current liabilities
Accounts payable	10,797	10,610
Accrued liabilities	7,652	9,220
Unearned revenue and contract liabilities	2,336	2,455
Current portion of lease liability	3,058	3,000
Current portion of long-term debt, net	345	25,201
Total current liabilities	24,188	50,486
Private warrants liability	149,635	82,860
Long-term lease liability, net	23,952	24,175
Long-term debt, net	31,316	31,386
Other long-term liabilities	938	1,250
Total liabilities	230,029	190,157
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 85,339,145 and 84,535,640 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	9	8
Additional paid-in capital	435,782	414,819
Accumulated deficit	(153,517)	(58,783)
Total stockholders’ equity	282,274	356,044
Total liabilities and stockholders’ equity	$ 512,303	$ 546,201

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	85,339,145	84,535,640
Common stock, shares outstanding	85,339,145	84,535,640

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total revenue	$ 13,181	$ 10,598
Costs and expenses:
Cost of revenue	11,725	7,429
Selling, general and administrative	10,120	2,980
Research and development	2,619	1,247
Total costs and expenses	24,464	11,656
Loss from operations	(11,283)	(1,058)
Nonoperating income (expense):
Loss on remeasurement of private warrants	(80,697)	0
Interest expense	(200)	(713)
Loss on debt extinguishment	(2,604)	0
Other income (expense), net	50	90
Total nonoperating expenses	(83,451)	(623)
Loss before income taxes	(94,734)	(1,681)
Income tax expense	0	0
Net loss	$ (94,734)	$ (1,681)
Basic and diluted net loss per share (in Dollars per share)	$ (1.12)	$ (0.06)
Weighted average number of common shares used to compute basic and diluted net loss per common share (in Shares)	84,708,137	27,761,717
Products
Revenue
Total revenue	$ 11,024	$ 9,179
Services
Revenue
Total revenue	$ 2,157	$ 1,419

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (94,734)	$ (1,681)
Adjustments to reconcile net loss to net cash used in operating activities
Loss on remeasurement of private warrants	80,697	0
Share-based compensation	6,665	147
Depreciation and amortization	2,100	870
Loss on writeoff of deferred loan costs	1,900	0
Amortization of debt issuance costs and debt discounts	82	233
Amortization of right-of-use assets and lease liability	41	128
Other	38	90
Changes in operating assets and liabilities - net of acquisitions:
Accounts receivable, net	(3,509)	(1,736)
Inventories	(3,204)	(3,133)
Prepaid expenses and other current assets	(1,498)	(42)
Other assets	125	(191)
Accounts payable	(669)	268
Accrued and other long-term liabilities	(2,123)	(156)
Unearned revenue and contract liabilities	(119)	(412)
Net cash used in operating activities	(14,208)	(5,615)
Cash flows from investing activities
Purchases of property, plant and equipment	(23,893)	(15,340)
Net cash used in investing activities	(23,893)	(15,340)
Cash flows from financing activities
Principal payments on long-term debt	(27,037)	(404)
Proceeds from exercise of stock options	1,191	0
Proceeds from long-term debt	120	2,435
Payments for debt issuance costs	(25)	(27)
Proceeds from NMTC financing	0	91
Proceeds from issuance of common stock, net of issuance costs	(815)	24,916
Net cash (used in) provided by financing activities	(26,566)	27,011
Net (decrease) increase in cash and cash equivalents and restricted cash	(64,667)	6,056
Cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash-beginning of period	379,897	6,261
Cash and cash equivalents and restricted cash-end of period	$ 315,230	$ 12,317

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance, beginning of period (in Shares) at Dec. 31, 2019		25,371,186
Balance, beginning of period at Dec. 31, 2019		$ 3	$ 66,503	$ (49,930)
Issuance of common stock		3,634,123
Issuance of common stock, value		$ 0
Fair value of Private Warrants converted to Public Warrants			0
Stock-based compensation			147
Stock issued under stock compensation plan			0
Share proceeds receivable			91
Debt discount beneficial conversion feature			93
Stock issued, net of capital issuance costs			24,916
Net loss	$ (1,681)			(1,681)
Balance, end of period (in Shares) at Mar. 31, 2020		29,005,309
Balance, end of period at Mar. 31, 2020	40,142	$ 3	91,750	(51,611)
Balance, beginning of period (in Shares) at Dec. 31, 2020		84,535,640
Balance, beginning of period at Dec. 31, 2020	$ 356,044	$ 8	414,819	(58,783)
Issuance of common stock	3,093,984	803,505
Issuance of common stock, value		$ 1
Fair value of Private Warrants converted to Public Warrants			13,922
Stock-based compensation			6,665
Stock issued under stock compensation plan			1,191
Share proceeds receivable			0
Debt discount beneficial conversion feature			0
Stock issued, net of capital issuance costs			(815)
Net loss	$ (94,734)			(94,734)
Balance, end of period (in Shares) at Mar. 31, 2021		85,339,145
Balance, end of period at Mar. 31, 2021	$ 282,274	$ 9	$ 435,782	$ (153,517)

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc. (“Danimer”) together with its subsidiaries (collectively referred to as the “Company”) is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. The Company’s common stock and public warrants are listed on the New York Stock Exchange under the symbols “DNMR” and “DNMR WS”, respectively. We have prepared our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the rules and regulations of the United States Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all adjustments, which are of a normal recurring nature, necessary to present fairly our financial position, results of operations, stockholders’ equity, and cash flows at the dates and for the periods presented. These Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and the notes thereto included in our Amended Annual Report on Form 10-K/A for the year ended December 31, 2020. Results for interim periods are not necessarily indicative of the results for the year. We cannot predict the ongoing impact of the COVID-19 pandemic on the increased volatility in global economic and political environments, uncertain market demand for its products, supply chain disruptions, possible workforce unavailability, exchange rate and commodity price volatility and availability of financing, and their impact to our total revenue, production volumes, costs and overall financial condition and available funding. In preparing these Condensed Consolidated Financial Statements in conformity with U.S. GAAP, we have considered and, where appropriate, reflected the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies. Recently Issued or Adopted Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our Condensed Consolidated Financial Statements.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combination	Note 2. Business Combination Live Oak Acquisition Corp. (“Live Oak”), was originally incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a business combination (“Business Combination”) with Meredian Holdings Group, Inc. (“Legacy Danimer”) with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. On December 29, 2020, we consummated a business combination with Legacy Danimer pursuant to the Merger Agreement. Pursuant to ASC 805, for financial accounting and reporting purposes, Legacy Danimer was deemed the accounting acquirer, we were treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Effectively, the Business Combination was treated as the equivalent of Legacy Danimer issuing stock for the net assets of Live Oak, accompanied by a recapitalization. Under this method of accounting, the historical financial statements of Legacy Danimer are our historical financial statements. The net assets of Live Oak are stated at historical costs, with no goodwill or other intangible assets recorded in accordance with U.S. GAAP and are consolidated with Legacy Danimer’s financial statements on the Closing Date.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Note 3. Inventories Inventories consisted of the following: March 31, December 31, (in thousands) 2021 2020 Raw materials $ 7,956 $ 6,825 Work in progress 56 133 Finished goods and related items 8,834 6,684 Total inventories $ 16,846 $ 13,642

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Note 4. Property, Plant and Equipment Property, plant and equipment, net, consisted of the following: Estimated Useful Life March 31, December 31, (in thousands) (Years) 2021 2020 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful 20,932 20,932 Buildings 15 - 40 2,089 2,089 Machinery and equipment 5 - 20 66,881 64,164 Motor vehicles 7 - 10 825 693 Furniture and fixtures 7 - 10 226 221 Office equipment 3 - 10 2,100 2,089 Construction in progress N/A 58,037 36,146 151,182 126,426 Accumulated depreciation and amortization ( 21,605 ) ( 19,631 ) Property, plant and equipment, net $ 129,577 $ 106,795 We reported depreciation and amortization expense (which includes amortization of patents) within the Condensed Consolidated Statements of Operations as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cost of revenue $ 1,839 $ 683 Selling, general and administrative 96 29 Research and development 165 158 Total depreciation and amortization expense $ 2,100 $ 870 Construction in progress consists primarily of the conversion and build-out of our new facility in Winchester, Kentucky. Property, plant and equipment includes capitalized interest of $ 5.3 million and $ 5.1 million as of March 31, 2021 and December 31, 2020, respectively. For the three months ended March 31, 2021 and 2020, interest costs of $ 0.2 million and $ 0.8 million, respectively, were capitalized to property, plant and equipment. At March 31, 2021 and December 31, 2020 , prepaid expenses and other current assets included $ 0.8 million of equipment that we have classified as held for sale. This equipment was sold in April 2021 for its carrying value.

Patents

Patents	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 5. Patents The majority of the patents were purchased from another commercial corporation, but we also capitalize patent defense and application costs. Patent costs are amortized on a straight-line basis over the estimated remaining useful lives at acquisition of the applicable patents which range from 13 to 16 years. At March 31, 2021 and December 31, 2020, the gross carrying value of patents subject to amortization was approximately $ 7.8 million and $ 7.8 million, respectively. Accumulated amortization was approximately $ 6.6 million and $ 6.5 million at March 31, 2021 and December 31, 2020, respectively. Amortization expense was $ 0.1 million for each of the quarters ended March 31, 2021 and 2020 and is included in research and development costs in the Condensed Consolidated Statements of Operations. At March 31, 2021 and December 31, 2020, capitalized patent acquisition and defense costs not yet subject to amortization were $ 0.6 million and $ 0.5 million, respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2021
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 6. Accrued Liabilities The components of accrued liabilities were as follows: March 31, December 31, (in thousands) 2021 2020 Compensation and related expenses $ 4,303 $ 5,395 Legal settlement 1,250 1,250 Transaction costs and other legal fees 755 1,293 Construction in progress expenditures 551 531 Other 793 751 Total accrued liabilities $ 7,652 $ 9,220

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 7. Income Taxes Our effective income tax rate was zero for the periods ended March 31, 2021 and March 31, 2020 because we reported net losses in each period and we continued to provide a full valuation allowance against our net deferred tax assets. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment.

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Operating Leases	Note 8. Operating Leases We reported operating lease costs within the Condensed Consolidated Statements of Operations as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cost of revenue $ 530 $ 216 Selling, general and administrative 51 455 Research and development 144 115 Total operating lease cost $ 725 $ 786

Private Warrants

Private Warrants	3 Months Ended
	Mar. 31, 2021
Text Block [Abstract]
Private Warrants	Note 9. Private Warrants At March 31, 2021 and December 31, 2020, there were 5,481,153 and 6,000,000 outstanding warrants, respectively to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, that had been privately placed prior to the Business Combination ("Private Warrants"). The warrants are exercisable at any time after May 7, 2021 , and we do not have any right to compel the exercise or redemption of the Private Warrants. If the Private Warrants are transferred, assigned, or sold to anyone other than the Sponsor or its permitted transferee, they become Public Warrants (as defined in Note 11). On December 28, 2025 , any remaining outstanding Private Warrants will expire. During the quarter ended March 31, 2021, holders of 518,847 Private Warrants sold them, and those Private Warrants became Public Warrants. We valued these Private Warrants on each sale date using the Black Scholes model and reclassified the fair value of each Private Warrant to additional paid in capital. These warrants meet the definition of a derivative instrument and are reported as liabilities in the Condensed Consolidated Balance Sheet at March 31, 2021 and December 31, 2020 , with changes in the fair value of the Private Warrants recorded in earnings. The Private Warrants are Level 3 financial instruments. A rollforward of the private warrants liability is below. (in thousands) Balance at December 31, 2020 $ ( 82,860 ) Loss on remeasurement of private warrants ( 80,697 ) Fair value of Private Warrants sold 13,922 Balance at March 31, 2021 $ ( 149,635 ) The table below sets forth the inputs to our Black-Scholes models and the fair values of the Private Warrants we calculated. As Of Three months ended As Of March 31, 2021 March 31, 2021 December 31, 2020 Share price of our common stock $ 37.75 $ 34.15 - $ 44.26 $ 23.51 Expected annual dividend yield (1) 0 % 0 % 0 % Expected volatility (2) 40 % 40 % 40.0 % Risk-free rate of return (3) 0.85 % 0.85 % 0.36 % Expected warrant term (years) (4) 4.74 4.74 - 4.77 4.99 Fair value determined per warrant $ 27.30 $ 23.83 - $ 33.65 $ 13.81 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgement and as such, expected volatility is a Level 3 input. (3) We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates. (4) The expected option terms are equal to the remaining contractual life of the Private Warrants at each measurement date.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 10. Debt The components of long-term debt were as follows: (in thousands) March 31, December 31, 2021 2020 2019 Term loan $ — $ 27,000 Subordinated term loan 10,205 10,171 NMTC notes 21,000 21,000 Paycheck Protection Program loan 1,776 1,776 Vehicle and equipment notes 418 329 Mortgage notes 260 266 Total $ 33,659 $ 60,542 Less: Total unamortized debt issuance costs ( 1,998 ) ( 3,955 ) Less: Current cash maturities of $27,140, net of current portion of debt issuance costs at December 31, 2020 ( 345 ) ( 25,201 ) Total long-term debt $ 31,316 $ 31,386 2019 Term Loan In March 2019, we entered into a credit agreement (“2019 Term Loan”) for a $ 30 million term loan maturing on October 13, 2023 . Principal payments were due in quarterly payments of $ 375,000 beginning April 1, 2019 with the outstanding principal balance due at maturity. The 2019 Term Loan was secured by all real and personal property of Danimer Scientific Holdings, LLC (“DSH”) and its subsidiaries. The 2019 Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio and fixed charge coverage ratio, each of which became more restrictive over time. In July 2020, we modified the 2019 Term Loan such that the applicable margin in the interest rate formula (formerly calculated as the greater of (a) 2.25 % or (b) Three month LIBOR, plus 4.5 %) changed from 4.5% to a five-level tiered amount ranging from 4.5% if the consolidated senior leverage ratio, as defined in the Term Loan, was less than 1.5, to as high as 6.35 % if the consolidated senior leverage ratio was greater than 2.25. When the amendment was executed, the applicable margin was 6.35%. On January 29, 2021, we voluntarily paid off and terminated our 2019 Term Loan. All related liens and security interests in our assets and guarantees were terminated and released. We settled the 2019 Term Loan for $ 27.7 million including the outstanding principal amount of $ 27.0 million, a prepayment fee of $ 0.5 million and $ 0.2 million in accrued unpaid interest. We recognized a loss of $ 2.6 million upon extinguishment due to the prepayment and related fees and the write off of unamortized debt issuance costs. Subordinated Term Loan In March 2019, we, through a subsidiary (DSH), entered into a subordinated second credit agreement (“Subordinated Term Loan”) for $ 10 million in term loans consisting of two loans in the amounts of $ 5.5 million and $ 4.5 million with essentially the same terms. The term loans mature on February 13, 2024 and require monthly interest only payments, with the outstanding principal balance due at maturity. The base interest rate is the “Prime Rate” as quoted by the Wall Street Journal (adjusted each calendar quarter; 3.25 % and 3.25 % at March 31, 2021 and December 31, 2020, respectively) plus 2.75 %. We have the option to pay up to two percent ( 2 %) in any interest payable in any fiscal quarter by adding such interest payment to the principal balance of the related note (“PIK Interest”). During the year ended December 31, 2020, we used the PIK Interest option and an additional $ 0.2 million was included in the principal balance at December 31, 2020. The Subordinated Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio, fixed charge coverage ratio and adjusted EBITDA, certain of which became more restrictive over time. On March 18, 2021, we amended the Subordinated Term Loan to, among other things, change the base rate from the prime rate to LIBOR, lower the applicable margin to 2 % from 2.75%, remove certain prepayment requirements, convert the financial covenants to "springing" covenants that do not apply as long as DSH has at least $ 10 million of unrestricted cash on deposit, increase the capital expenditure covenant, and restrict our ability to prepay the loan until after July 1, 2022. The Subordinated Term Loan remains secured by all real and personal property of DSH and its subsidiaries but is subordinated to all other existing lenders. At March 31, 2021, we were in compliance with all financial covenants. Paycheck Protection Program Loan In April 2020, we received $ 1.8 million under the Paycheck Protection Program (the “PPP Loan”). The PPP Loan had a two-year term and bore interest at a rate of 1.0 % per annum. Monthly principal and interest payments were deferred for six months after the date of disbursement. The promissory note issued in connection with the PPP Loan contained events of default and other provisions customary for a loan of this type. On December 11, 2020, we submitted an application for forgiveness of the PPP loan. In connection with the Business Combination, we entered into an Escrow Agreement with the PPP lender and on the Closing Date deposited $ 1.8 million in escrow representing the principal, accrued interest, and escrow fee to pay the loan in full. We have classified the amounts in escrow as restricted cash in the Condensed Consolidated Balance Sheets at March 31, 2021 and December 31, 2020. On April 12, 2021, we received notice that our PPP Loan has been forgiven. We expect that $ 1.8 million, representing principal and interest earned on the balance in escrow, and net of associated fees, will be released to us from escrow during the quarter ending June 30, 2021. Asset-based Lending Arrangement On April 29, 2021, we entered into a credit facility with Truist Bank that includes a $ 20.0 million variable interest rate asset-based lending arrangement and a $ 1.0 million capital expenditure line of credit with customary terms and conditions. These arrangements mature on April 29, 2026 .

Equity

Equity	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Equity	Note 11. Equity During the quarter ended March 31, 2021, we completed a Registration Form on Form S-8 and incurred $ 0.8 million in associated costs, which were charged against additional paid in capital. Public Warrants At December 31, 2020, there were 10,000,000 outstanding publicly traded warrants to purchase shares of our common stock that were issued by Live Oak, prior to the Business Combination, with an exercise price of $ 11.50 per share, subject to adjustments (“Public Warrants”). The Public Warrants are exercisable at any time after May 7, 2021. Once the Public Warrants become exercisable, we may redeem them at a price of $ 0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of our common stock equals or exceeds $ 18.00 per share for any 20-trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrant holders. The Public Warrants will expire on December 28, 2025 or earlier upon redemption or liquidation. The Public Warrants qualify as equity instruments and we have included them in additional paid-in capital in the Condensed Consolidated Balance Sheets at March 31, 2021 and December 31, 2020. During the quarter ended March 31, 2021, holders of 518,847 Private Warrants sold them, and those Private Warrants became Public Warrants. On May 14, 2021, we notified holders of the Public Warrants of our intent to redeem them on June 16, 2021. Non-Plan Legacy Danimer Options and Warrants Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $ 30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase 279,253 shares of our common stock with a weighted average exercise price of $ 3.28 per share, which remain outstanding at March 31, 2021. As of December 29, 2020, Legacy Danimer had 55,139 warrants outstanding with an exercise price of $ 30 per share. In connection with the Business Combination, these options were converted to options to purchase 506,611 shares of our common stock with an exercise price of $ 3.28 per share, and were exercised during the quarter ended March 31, 2021 on a cashless basis by issuing 435,961 shares. Anti-dilutive Instruments The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive.  Three Months Ended March 31,   2021  2020 Employee stock options 10,682,969  11,108,755 Public Warrants  10,518,847 - Private Warrants  5,481,153  - Restricted Shares 3,035,676 - Legacy Danimer options  279,253  1,906,540 Legacy Danimer warrants  - 506,611 Total excluded instruments 29,997,898 13,521,906

Revenue

Revenue	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Note 12. Revenue We recognize revenue from product sales and services in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). We derive our revenues primarily from: 1) product sales of developed compostable resins based on polylactic acid (“PLA”), polyhydroxyalkanoates (“PHA”), and other renewable materials; and 2) research and development (“R&D”) services related to developing customized formulations of biodegradable resins based on PHA. We generally produce and sell finished products, for which we recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price. We defer certain contract fulfillment costs. These costs are amortized to cost of revenue on a per-pound basis as we sell the related product. During the quarter ended March 31, 2021, we charged $ 0.2 million of fulfillment costs to cost of revenue. At March 31, 2021 and December 31, 2020 we had $ 1.4 million and $ 1.5 million, respectively, of contract assets recorded related to these fulfillment costs. R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based specific solution designed to the customer’s specifications, which may involve a single or multiple performance obligations. At the inception of our R&D services contracts, customers generally pay consideration at the commencement of the agreement and at milestones as outlined in the contracts. We recognize contract liabilities for such consideration initially, and then reduce each contract liability by recognizing revenue for our R&D services over time by measuring progress with an input method based on personnel hours incurred to date as a percentage of total estimated personnel hours for each performance obligation identified within each contract. The following table shows the significant changes in the contract liability balance for the quarters ended March 31, 2021 and 2020: Three Months Ended March 31, (in thousands) 2021 2020 Beginning balance $ 2,455 $ 4,580 Revenue recognized ( 1,737 ) ( 411 ) Unearned consideration received 1,618 - Ending balance $ 2,336 $ 4,169

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 13. Stock-Based Compensation 2020 Equity Incentive Plans In connection with the Business Combination, on December 29, 2020, our stockholders approved the 2020 Incentive Plan and the 2020 Employee Stock Purchase Plan (the “2020 ESPP Plan”). The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. Up to 3,093,984 shares of our common stock were authorized to be issued with respect to awards under the 2020 Incentive Plan. This limit is subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization. The 2020 ESPP Plan provides for the sale of our common stock to our employees through payroll withholding at a discount of 15 % from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. The first offering period under the 2020 ESPP Plan commenced on April 1, 2021. Restricted Shares On March 10, 2021, we completed a Registration Form on Form S-8 to register the shares under the 2020 Equity Incentive Plan and the 2020 ESPP Plan. On this date, a grant of 3,035,676 shares of restricted stock was effective. The restrictions on half of these shares lapse ratably on the first, second, and third anniversaries of the grant date. The fair value of these shares on the date of grant was $ 37.09 and we are recognizing the compensation expense for these shares on a straight-line basis from the grant date through December 29, 2023. The restrictions on the other half of these shares lapse as follows: 1. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2021. 2. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2022. 3. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2023. To reflect the effect of this market condition on the vesting of these restricted shares, we valued them using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. A fair value is determined for each potential outcome. The grant date fair value of these restricted shares is the average of the fair values calculated for each potential outcome, or $ 36.57 . We are recognizing the compensation expense for these shares on a straight-line basis from the grant date through December 29, 2023. No other grants of restricted shares have been made. Stock Options A summary of stock option activity under our equity plans for the quarter ended March 31, 2021 follows:   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2020  11,008,533  $ 13.94  8.4  $ 105,341,482 Granted  37,500 45.41   Exercised  ( 363,064 ) 3.28   15,744,316 Balance, March 31, 2021  10,682,969  $ 14.41  8.0  $ 249,345,242      March 31, 2021:     Exercisable  4,791,353  $ 4.67  5.9  $ 180,873,576 Vested and expected to vest  10,682,969  $ 14.41  8.0  $ 249,345,242 The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on the respective exercise dates or on March 31, 2021, as applicable. The weighted average grant-date fair values of options granted during the quarter ended March 31, 2021 was $ 18.52 per option. We have estimated the fair values of our option awards on the date of grant using the Black-Scholes option pricing model with the following assumptions:   Three months ended March 31, 2021 Expected annual dividend yield (1)  0.00 % Expected volatility (2)  41.50 % Risk-free rate (3)  1.05 % Expected option term (years) (4)  6.00 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term. (3) We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date. (4) We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14. As of March 31, 2021, there was $ 157.1 million of unrecognized compensation cost related to nonvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of 2.7 years. During the quarter ended December 31, 2020, we awarded 1,466,874 stock options that are contingent upon on shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred and which we determined is not a perfunctory exercise, therefore no accounting grant date has been established. As a result, these awards are not reflected in our Consolidated Financial Statements.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties upon production and sale of PHAs. The royalty is $ 0.05 per pound for the first 500 million pounds of PHA sold and decreases to $ 0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. We incurred approximately $ 0.1 million and $ 0 in royalties during the quarters ended March 31, 2021 and March 31, 2020, respectively. In November 2015, we terminated a former executive and terminated our contract with an advisory firm (the “Advisory Contract”), pursuant to which we, through the advisory firm, engaged the individual as an executive of the Company. In December 2015, we deemed the Advisory Contract, together with all related arrangements in connection therewith, void, including any share issuances in connection with such arrangements. We filed suit against the former executive and the advisory firm during 2016, and various counterclaims were filed by the former executive and the advisory firm. During the third quarter of 2020, this matter was settled and we agreed to pay $ 8 million to resolve all outstanding claims, the executive agreed to the cancellation of any shares issued to such executive pursuant to the Advisory Contract and related arrangements, and the exchange of mutual releases among the parties. The remaining unpaid liability is included in accrued liabilities ($ 1.3 million and $ 1.3 million) and other long-term liabilities ($0. 9 million and $ 1.3 million) in the Condensed Consolidated Balance Sheets at March 31, 2021 and December 31, 2020, respectively. In conjunction with our planned expansion of our Winchester, Kentucky production facility, we had outstanding noncancellable purchase orders of $ 44.5 million at March 31, 2021. We expect to satisfy these commitments during fiscal 2021. We may be a party to other legal claims and actions incidental to our business. We do not believe such matters, if any, are material, either individually or in the aggregate, to the Consolidated Financial Statements.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events Capital Structure-related Events On April 12, 2021, we received notice that our PPP Loan has been forgiven. We expect that $ 1.8 million, representing principal and interest earned on the balance in escrow, and net of associated fees, will be released to us from escrow during the quarter ending June 30, 2021. On April 29, 2021, we entered into a credit facility with Truist Bank that includes a $ 20.0 million variable interest rate asset-backed lending arrangement and a $ 1.0 million capital expenditure line with customary terms and conditions. These arrangements mature on April 29, 2026 . On May 14, 2021, we notified holders of the Public Warrants of our intent to redeem them on June 16, 2021. Litigation-related Event On May 14, 2021, a class action complaint was filed in the United States District Court for the Eastern District of New York by Darryl Keith Rosencrants, individually and on behalf of all others similarly situated against Danimer Scientific, Inc., Stephen E. Croskrey, John A. Dowdy, III, John P. Amboian, Richard J. Hendrix, Christy Basco, Philip Gregory Calhoun, Gregory Hunt, Isao Noda, and Stuart W. Pratt (collectively, “Defendants”). The alleged class consists of all persons and entities other than Defendants that purchased or otherwise acquired Danimer securities between December 30, 2020 and March 19, 2021 (the “Class Period”). Plaintiff is seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The complaint is premised upon various allegations that throughout the Class Period, Defendants allegedly made materially false and misleading statements regarding, among other things, Danimer’s business, operations, and compliance policies. Plaintiff seeks the following remedies: (i) determining that the lawsuit may be maintained as a class action under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying Plaintiff as the class representative, (iii) requiring Defendants to pay damages allegedly sustained by Plaintiff and the class by reason of the aforesaid acts alleged in the complaint, and (iv) awarding Plaintiff and the other members of the class pre-judgment and post-judgment interest, as well as their reasonable attorneys’ fees, expert fees and other costs. We are unable to estimate the amount or range of loss, if any, and therefore have not established a loss provision. The complaint repeats certain allegations, which are already in the public domain. Defendants deny the allegations contained in the complaint, believe this lawsuit is without any merit and intend to defend it vigorously.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business Danimer Scientific, Inc. (“Danimer”) together with its subsidiaries (collectively referred to as the “Company”) is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. The Company’s common stock and public warrants are listed on the New York Stock Exchange under the symbols “DNMR” and “DNMR WS”, respectively. We have prepared our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the rules and regulations of the United States Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all adjustments, which are of a normal recurring nature, necessary to present fairly our financial position, results of operations, stockholders’ equity, and cash flows at the dates and for the periods presented. These Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and the notes thereto included in our Amended Annual Report on Form 10-K/A for the year ended December 31, 2020. Results for interim periods are not necessarily indicative of the results for the year. We cannot predict the ongoing impact of the COVID-19 pandemic on the increased volatility in global economic and political environments, uncertain market demand for its products, supply chain disruptions, possible workforce unavailability, exchange rate and commodity price volatility and availability of financing, and their impact to our total revenue, production volumes, costs and overall financial condition and available funding. In preparing these Condensed Consolidated Financial Statements in conformity with U.S. GAAP, we have considered and, where appropriate, reflected the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies.
Recently Issued or Adopted Accounting Pronouncements	Recently Issued or Adopted Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our Condensed Consolidated Financial Statements.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: March 31, December 31, (in thousands) 2021 2020 Raw materials $ 7,956 $ 6,825 Work in progress 56 133 Finished goods and related items 8,834 6,684 Total inventories $ 16,846 $ 13,642

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: Estimated Useful Life March 31, December 31, (in thousands) (Years) 2021 2020 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful 20,932 20,932 Buildings 15 - 40 2,089 2,089 Machinery and equipment 5 - 20 66,881 64,164 Motor vehicles 7 - 10 825 693 Furniture and fixtures 7 - 10 226 221 Office equipment 3 - 10 2,100 2,089 Construction in progress N/A 58,037 36,146 151,182 126,426 Accumulated depreciation and amortization ( 21,605 ) ( 19,631 ) Property, plant and equipment, net $ 129,577 $ 106,795
Schedule of depreciation and amortization expense	We reported depreciation and amortization expense (which includes amortization of patents) within the Condensed Consolidated Statements of Operations as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cost of revenue $ 1,839 $ 683 Selling, general and administrative 96 29 Research and development 165 158 Total depreciation and amortization expense $ 2,100 $ 870

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	The components of accrued liabilities were as follows: March 31, December 31, (in thousands) 2021 2020 Compensation and related expenses $ 4,303 $ 5,395 Legal settlement 1,250 1,250 Transaction costs and other legal fees 755 1,293 Construction in progress expenditures 551 531 Other 793 751 Total accrued liabilities $ 7,652 $ 9,220

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Schedule of operating lease costs	We reported operating lease costs within the Condensed Consolidated Statements of Operations as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cost of revenue $ 530 $ 216 Selling, general and administrative 51 455 Research and development 144 115 Total operating lease cost $ 725 $ 786

Private Warrants (Tables)

Private Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Schedule of Private Warrants Fair Value Measurement Valuation	The table below sets forth the inputs to our Black-Scholes models and the fair values of the Private Warrants we calculated. As Of Three months ended As Of March 31, 2021 March 31, 2021 December 31, 2020 Share price of our common stock $ 37.75 $ 34.15 - $ 44.26 $ 23.51 Expected annual dividend yield (1) 0 % 0 % 0 % Expected volatility (2) 40 % 40 % 40.0 % Risk-free rate of return (3) 0.85 % 0.85 % 0.36 % Expected warrant term (years) (4) 4.74 4.74 - 4.77 4.99 Fair value determined per warrant $ 27.30 $ 23.83 - $ 33.65 $ 13.81 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgement and as such, expected volatility is a Level 3 input. (3) We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates. (4) The expected option terms are equal to the remaining contractual life of the Private Warrants at each measurement date.
Summary of Rollforward of Private Warrants Liability	A rollforward of the private warrants liability is below. (in thousands) Balance at December 31, 2020 $ ( 82,860 ) Loss on remeasurement of private warrants ( 80,697 ) Fair value of Private Warrants sold 13,922 Balance at March 31, 2021 $ ( 149,635 )

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of long-term debt	The components of long-term debt were as follows: (in thousands) March 31, December 31, 2021 2020 2019 Term loan $ — $ 27,000 Subordinated term loan 10,205 10,171 NMTC notes 21,000 21,000 Paycheck Protection Program loan 1,776 1,776 Vehicle and equipment notes 418 329 Mortgage notes 260 266 Total $ 33,659 $ 60,542 Less: Total unamortized debt issuance costs ( 1,998 ) ( 3,955 ) Less: Current cash maturities of $27,140, net of current portion of debt issuance costs at December 31, 2020 ( 345 ) ( 25,201 ) Total long-term debt $ 31,316 $ 31,386

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive.  Three Months Ended March 31,   2021  2020 Employee stock options 10,682,969  11,108,755 Public Warrants  10,518,847 - Private Warrants  5,481,153  - Restricted Shares 3,035,676 - Legacy Danimer options  279,253  1,906,540 Legacy Danimer warrants  - 506,611 Total excluded instruments 29,997,898 13,521,906

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of changes in contract liability balance	The following table shows the significant changes in the contract liability balance for the quarters ended March 31, 2021 and 2020: Three Months Ended March 31, (in thousands) 2021 2020 Beginning balance $ 2,455 $ 4,580 Revenue recognized ( 1,737 ) ( 411 ) Unearned consideration received 1,618 - Ending balance $ 2,336 $ 4,169

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity under our equity plans	A summary of stock option activity under our equity plans for the quarter ended March 31, 2021 follows:   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2020  11,008,533  $ 13.94  8.4  $ 105,341,482 Granted  37,500 45.41   Exercised  ( 363,064 ) 3.28   15,744,316 Balance, March 31, 2021  10,682,969  $ 14.41  8.0  $ 249,345,242      March 31, 2021:     Exercisable  4,791,353  $ 4.67  5.9  $ 180,873,576 Vested and expected to vest  10,682,969  $ 14.41  8.0  $ 249,345,242
Schedule of option award on the date of grant using the Black-Scholes option	We have estimated the fair values of our option awards on the date of grant using the Black-Scholes option pricing model with the following assumptions:   Three months ended March 31, 2021 Expected annual dividend yield (1)  0.00 % Expected volatility (2)  41.50 % Risk-free rate (3)  1.05 % Expected option term (years) (4)  6.00 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term. (3) We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date. (4) We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14.

Basis of Presentation (Details)

Basis of Presentation (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Description of Business and Basis of Presentation (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Business Combination (Details)

Business Combination (Details)	3 Months Ended
	Mar. 31, 2021shares
Business Combination (Details) [Line Items]
Share of common stock (in Shares)	435,961

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of inventory [Abstract]
Raw materials	$ 7,956	$ 6,825
Work in progress	56	133
Finished goods and related items	8,834	6,684
Total inventories	$ 16,846	$ 13,642

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - Schedule of Property, plant, and equipment, net - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 151,182	$ 126,426
Accumulated depreciation and amortization	(21,605)	(19,631)
Property, plant and equipment, net	$ 129,577	106,795
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Property and equipment, gross	$ 92	92
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 20,932	20,932
Estimated Useful Life	Shorter of usefullife or lease term
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,089	2,089
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	15 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 66,881	64,164
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 825	693
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 226	221
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,100	2,089
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 58,037	$ 36,146

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of depreciation and amortization expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	$ 2,100	$ 870
Cost of revenue [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	1,839	683
Selling, general, and administrative [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	96	29
Research & development [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	$ 165	$ 158

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, plant, and equipment includes capitalized interest	$ 5.3		$ 5.1
Property, Plant and Equipment interest costs	0.2	$ 0.8
Prepaid expenses and other current assets	$ 0.8		$ 0.8

Patents (Details)

Patents (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross			$ 7.8
Finite-Lived Intangible Assets, Accumulated Amortization	$ 6.6
Intangible asset not yet subject to amortization	0.6		0.5
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	7.8
Finite-Lived Intangible Assets, Accumulated Amortization			$ 6.5
Patents [Member] | Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 0.1	$ 0.1
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	13 years

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Schedule of accrued liabilities [Abstract]
Compensation and related expenses	$ 4,303	$ 5,395
Legal settlement	1,250	1,250
Transaction costs and other legal fees	755	1,293
Construction in progress expenditures	551	531
Other	793	751
Total accrued liabilities	$ 7,652	$ 9,220

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

Operating Leases (Details) - Sc

Operating Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Operating lease cost	$ 725	$ 786
Cost of revenue [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Operating lease cost	530	216
Selling, general and administrative [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Operating lease cost	51	455
Research and development [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Operating lease cost	$ 144	$ 115

Private Warrants (Details)

Private Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 29, 2020
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding			10,000,000	55,139
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50		$ 30
Class of Warrant or Right, Date from which Warrants or Rights Exercisable	May 7, 2021
Warrants and Rights Outstanding, Maturity Date	Dec. 28, 2025
Warrants and Rights Outstanding	$ 518,847
Fair Value Adjustment of Warrants	$ 80,697	$ 0
Public Warrants
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	5,481,153		6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50
Warrants and Rights Outstanding	$ 518,847

Private Warrants - Summary of R

Private Warrants - Summary of Rollforward of Private Warrants Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Class of Warrant or Right [Line Items]
Balance at December 31, 2020	$ (82,860)
Loss on remeasurement of private warrants	(80,697)	$ 0
Fair value of Private Warrants sold	13,922
Balance at March 31,2021	$ (149,635)

Private Warrants - Schedule of

Private Warrants - Schedule of Fair Value Valuation of Private Warrants (Details)		Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		27.30	13.81
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		37.75	23.51
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[1]	0	0
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[2]	0.40	0.400
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[3]	0.0085	0.36
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 8 months 26 days	4 years 11 months 26 days
Maximum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		33.65
Maximum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		44.26
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 9 months 7 days
Minimum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		23.83
Minimum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		34.15
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 8 months 26 days
[1]	We have not paid and do not currently anticipate paying a cash dividend on our common stock.
[2]	We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgement and as such, expected volatility is a Level 3 input.
[3]	We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates.
[4]	The expected option terms are equal to the remaining contractual life of the Private Warrants at each measurement date.

Debt (Details) - Schedule of lo

Debt (Details) - Schedule of long-term debt - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 33,659	$ 60,542
Less: Total unamortized debt issuance costs	(1,998)	(3,955)
Less: Current cash maturities of $27,140, net of current portion of debt issuance costs in 2020	(345)	(25,201)
Total long-term debt	31,316	31,386
2019 Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total		27,000
2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	10,205	10,171
NMTC Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	21,000	21,000
Paycheck Protection Program loan
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	1,776	1,776
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	418	329
Mortgage Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 260	$ 266

Debt (Details)

Debt (Details) - USD ($)	Apr. 29, 2021	Apr. 12, 2021	Mar. 18, 2021	Mar. 31, 2019	Jul. 31, 2020	Mar. 31, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Jan. 29, 2021	Apr. 30, 2020
Long-Term Debt (Details) [Line Items]
Unrestricted cash on deposit							$ 312,910,000		$ 377,581,000
Loss on writeoff of deferred loan costs							2,604,000	$ 0
Interest expense							$ 200,000	$ 713,000
2019 Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Maturity date				Oct. 13, 2023		Oct. 13, 2023
Aggregate principal amount				$ 30,000,000		$ 30,000,000
Principle payment				375,000
Interest rate formula, description					the applicable margin in the interest rate formula (formerly calculated as the greater of (a) 2.25% or (b) Three month LIBOR, plus 4.5%) changed from 4.5% to a five-level tiered amount ranging from 4.5% if the consolidated senior leverage ratio, as defined in the Term Loan, was less than 1.5, to as high as 6.35% if the consolidated senior leverage ratio was greater than 2.25.  When the amendment was executed, the applicable margin was 6.35%.
Prepaid total amount										$ 27,700,000
Outstanding principal amount										27,000,000
Prepayment fee										500,000
Accrued unpaid interest										$ 200,000
Debt instrument, basis spread on variable rate					2.25%
2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Subordinated term loan				10,000,000		$ 10,000,000
Interest rate basis						The base interest rate is the “Prime Rate” as quoted by the Wall Street Journal (adjusted each calendar quarter; 3.25% and 3.25% at March 31, 2021 and December 31, 2020, respectively) plus 2.75%. We have the option to pay up to two percent (2%) in any interest payable in any fiscal quarter by adding such interest payment to the principal balance of the related note (“PIK Interest”).
Debt base rate							3.25%		3.25%
Additional principal amount									$ 200,000
Option to pay interest payable							2.00%
2019 Subordinated Term Loan [Member] | Prime Rate [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			2.00%			2.75%
Paycheck Protection Program loan [Member]
Long-Term Debt (Details) [Line Items]
Aggregate principal amount											$ 1,800,000
Interest rate											1.00%
Escrow deposit											$ 1,800,000
Paycheck Protection Program loan [Member] | Subsequent Event [Member]
Long-Term Debt (Details) [Line Items]
Loan forgiven amount		$ 1,800,000
Minimum [Member] | 2019 Term Loan [Member] | Three Month LIBOR [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate					4.50%
Minimum [Member] | 2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Unrestricted cash on deposit			$ 10,000,000
Maximum [Member] | 2019 Term Loan [Member] | Three Month LIBOR [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate					6.35%
Term Loan One [Member] | 2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Subordinated term loan				5,500,000		$ 5,500,000
Term Loan Two [Member] | 2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Subordinated term loan				$ 4,500,000		$ 4,500,000
Truist bank [Member] | Subsequent Event [Member]
Long-Term Debt (Details) [Line Items]
Debt Instrument, Maturity Date	Apr. 29, 2026
Truist bank [Member] | Asset Backed Lending Arrangement [Member] | Subsequent Event [Member]
Long-Term Debt (Details) [Line Items]
Line of Credit Facility	$ 20,000,000
Truist bank [Member] | Capital Expenditure line [Member] | Subsequent Event [Member]
Long-Term Debt (Details) [Line Items]
Line of Credit Facility	$ 1,000,000

Equity (Details)

Equity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 29, 2020
Stockholders' Equity (Details) [Line Items]
Costs Incurred	$ 800,000
Warrants and Rights Outstanding	$ 518,847,000
Common Stock, Shares, Outstanding	85,339,145	84,535,640
Outstanding warrants (in Shares)		10,000,000	55,139
Warrant price per share	$ 11.50	$ 30
Shares, Issued	208,183
Weighted Average Exercise Price of per share (in Dollars per share)	$ 30
Exercisable and remained outstanding shares (in Dollars)	$ 15,744,316
Exercisable and remained outstanding ( in shares)	30,493
Conversion of Stock, Shares Converted	279,253	506,611
Class of Warrant or Right, Outstanding		10,000,000	55,139
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50	$ 30
Conversion of Stock, Shares Issued	435,961
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	$ 18.52
Weighted Average Exercise Price, Exercised (in Dollars per share)	3.28	$ 3.28
Public Warrants
Stockholders' Equity (Details) [Line Items]
Price per share	$ 18
Warrants and Rights Outstanding	$ 518,847,000
Outstanding warrants (in Shares)	5,481,153	6,000,000
Warrant price per share	$ 11.50
Redeemable outstanding warrants price	$ 0.01
Class of Warrant or Right, Outstanding	5,481,153	6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50

Equity (Details) Antidilutive S

Equity (Details) Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	29,997,898	13,521,906
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,682,969	11,108,755
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,481,153	0
Public Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,518,847	0
Restricted Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,035,676	0
Legacy Danimer warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	506,611
Legacy Danimer options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	279,253	1,906,540

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Fulfillment costs to cost of revenue	$ 0.2
Contract assets recorded related to fulfillment costs	$ 1.4	$ 1.5

Revenue (Details) - Change in C

Revenue (Details) - Change in Contract Liability Balance - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 2,455	$ 4,580
Revenue Recognized	(1,737)	(411)
Unearned consideration received	1,618
Ending Balance	$ 2,336	$ 4,169

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Mar. 10, 2021
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units	3,093,984
Employee share purchase plan, description	Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. The first offering period under the 2020 ESPP Plan commenced on April 1, 2021.
Fair value of restricted stock on the date of grant (in dollar per share)	$ 36.57		$ 37.09
Weighted average grant-date fair value of options granted (in Dollars per share)	$ 18.52
Restricted stock shares			3,035,676
Stock options		1,466,874
Unrecognized compensation cost related to nonvested stock options grant (in Dollars)	$ 157.1
Weighted-average over period	2 years 8 months 12 days
First anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	$ 24.20
Second anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	24.20
Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	$ 24.20
2020 ESPP [Member]
Stock-Based Compensation (Details) [Line Items]
ESPP plan, percentage of stock discount	15.00%
Share-based compensation, authorized shares	2,571,737

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans [Line Items]
Number of Shares, Beginning	11,008,533
Number of Shares, Granted	37,500
Number of Shares, Exercised	(363,064)
Number of Shares, Ending	10,682,969	11,008,533
Number of Shares, Exercisable	4,791,353
Number of Shares, Vested and expected to vest	10,682,969
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 13.94
Weighted Average Exercise Price, Granted (in Dollars per share)	45.41
Weighted Average Exercise Price, Exercised (in Dollars per share)	3.28	$ 3.28
Weighted Average Exercise Price, Ending (in Dollars per share)	14.41	$ 13.94
Weighted Average Exercise Price, Exercisable (in Dollars per share)	4.67
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share)	$ 14.41
Weighted Average Remaining Contractual Term (Years), Beginning	8 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years), Ending	8 years
Weighted Average Remaining Contractual Term (Years), Exercisable	5 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	8 years
Aggregate Intrinsic Value, Beginning (in Dollars)	$ 105,341,482
Aggregate Intrinsic Value, Exercised (in Dollars)	15,744,316
Aggregate Intrinsic Value, Ending (in Dollars)	249,345,242	$ 105,341,482
Aggregate Intrinsic Value, Exercisable (in Dollars)	180,873,576
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)	$ 249,345,242

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of option award on the date of grant using the Black-Scholes option	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Expected annual dividend yield	0.00%	[1]
Expected volatility	41.50%	[2]
Risk-free rate of return	1.05%	[3]
Expected option term (years)	6 years	[4]
[1]	We have not paid and do not currently anticipate paying a cash dividend on our common stock.
[2]	We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term.
[3]	We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date.
[4]	We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Royalty per share (in Pounds per share)	$ 0.05
Sold of PHA (in Pounds)	$ 500
Decrease royalty per share (in Pounds per share)	$ 0.025
Royalties amount	$ 0.1		$ 0
Outstanding claims amount		$ 8
Accrued expenses	1.3			$ 1.3
Other long-term liabilities	9			$ 1.3
Outstanding noncancellable purchase orders	$ 44.5

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	Apr. 29, 2021	Apr. 12, 2021	Apr. 30, 2020
Paycheck Protection Program loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 1.8
Subsequent Event [Member] | Truist bank [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date	Apr. 29, 2026
Subsequent Event [Member] | Truist bank [Member] | Capital Expenditure line [Member]
Subsequent Event [Line Items]
Line of Credit Facility	$ 1
Subsequent Event [Member] | Truist bank [Member] | Asset Backed Lending Arrangement [Member]
Subsequent Event [Line Items]
Line of Credit Facility	$ 20
Subsequent Event [Member] | Paycheck Protection Program loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Decrease, Forgiveness		$ 1.8